Rafael Holdings, Inc.

Rafael Holdings, Inc. Annual Report Summary for Everyday Investors

---

1. What Does Rafael Holdings Do?

Rafael Holdings operates in two main areas:

• Biotech Research: Their lead drug, Trappsol® Cyclo™ (targeting rare genetic disorder Niemann-Pick Disease), is in final Phase 3 trials. They also invest in cancer drug developers and medical devices.
• Real Estate: Owns office buildings in New Jersey, but vacancies are rising.

2023 Performance Snapshot: Biotech shows potential, but real estate income dropped sharply.

---

2. Financial Highlights

• Revenue: $5M (down 38% from $8M in 2022) – all from struggling real estate.
• R&D Spending: $15M (up 20% from 2022) – focused on Trappsol Cyclo trials.
• Net Loss: $12M (50% larger loss than last year).

Takeaway: Burning cash faster to push their rare disease drug forward.

---

3. Key Wins & Challenges

✅ Wins:

• Partnered to share drug development costs (critical as cash reserves shrink).
• A pancreatic cancer drug from their Cornerstone investment showed promise in trials.

❌ Challenges:

• Trappsol Cyclo trials delayed by 6 months.
• Office vacancies hurt real estate income.
• Potential side effects could derail their main drug.

---

4. Financial Health Check

• Cash Reserves: $50M (down from $65M in 2022).
• Monthly Burn Rate: ~$2M.
• Runway: ~2 years at current spending.
• Backup Plan: May sell real estate or issue new shares if Trappsol fails – both could hurt stock value.

---

5. Risks to Watch

• Competition: Rivals could create cheaper alternatives if patents fail.
• Tech Vulnerabilities: Heavy reliance on tech exposes them to cyberattacks (healthcare hacks rose 45% in 2023).
• Leadership Structure: One major shareholder controls decisions, limiting small investor influence.

---

6. How They Compare to Competitors

• Biotech: Small player, but Trappsol could dominate its niche (only ~500 U.S. patients yearly).
• Diversification: Unlike most competitors, Rafael juggles real estate, cancer drugs, rare diseases, and medical devices – a potential strength or weakness.

---

7. Leadership Changes

• Added a pharma-experienced board member to focus on Trappsol.
• Controlled by a single large investor – decisions are fast but less democratic.

---

8. What’s Next for 2024?

• Make-or-Break Moment: Phase 3 results for Trappsol Cyclo expected. Success could mean major stock gains; failure could trigger a crisis.
• Likely to sell real estate to fund biotech bets.
• Seeking partnerships to avoid diluting shares.

---

9. Market Trends Impacting Rafael

• 📈 Opportunity: FDA fast-tracks rare disease drugs, which could benefit Trappsol.
• 📉 Threat: New Jersey office vacancies hit 15-year highs, pressuring real estate income.

---

Key Takeaways for Investors

1. High Risk, High Reward: Rafael’s value hinges on Trappsol Cyclo’s Phase 3 results – typical success odds for this stage are ~30%.
2. Cash Burn Concerns: They have 2 years of runway but may need to sell assets or shares if trials fail.
3. Transparency Note: The company shared limited details about long-term real estate plans and backup strategies, which could concern risk-averse investors.

Final Verdict: Only suitable for investors who can stomach biotech volatility. Treat this like a speculative bet – potential for big returns, but equally likely to underperform. If Trappsol succeeds, it could be transformative. If not, the declining real estate business offers little safety net.

Investor Fit Checklist:
✅ Comfortable with high-risk biotech plays
✅ Willing to wait 12-18 months for trial results
❌ Avoid if you prioritize stable dividends or transparency